HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $53 to $60.